Axcelis Technologies (ACLS) ☆

Axcelis is an ion-implant specialist. The FY2025 10-K says implantation was 98.2% of 2025 revenue, sold as the Purion family of high energy, high current and medium current single-wafer implanters, the Ovation batch implanters, and aftermarket parts, upgrades and services. Its strongest ground is power devices. Axcelis calls itself 'a technology leader and supplier of choice in the implant-intensive power device segment', which made up 55% of the value of 2025 system shipments, and its Purion Power Series covers silicon carbide wafers. 2025 was a down year: revenue fell to $839.0 million from $1,017.9 million, systems backlog to $457.0 million from $645.8 million, and operating profit to $119.3 million from $210.8 million, while gross margin held at 44.9%. The 10-K names Applied Materials as the main rival and the only other full-range implant maker; other competitors include Sumitomo Heavy Industries Ion Technology, Nissin Ion Equipment, Advanced Ion Beam Technology and two Chinese developers. Among its 2026 goals the company lists 'Achieve market share leadership across all served markets', which it has not yet reached. On the Q2 2026 call (https://www.marketbeat.com/earnings/reports/2026-8-5-axcelis-technologies-inc-stock/), management said electric vehicles remain the number one driver of silicon carbide demand. It also said it expects its merger with Veeco, under which each Veeco share converts into 0.3575 Axcelis shares according to the 10-K, to close in the second half of 2026, pending approval in China.

Rating: narrow

Axcelis's FY2025 10-K describes a protected but contested position. On the durable side, it says 'Axcelis and Applied Materials are the only ion implant system manufacturers with a full range of implant products'. About 3,400 Axcelis products are in use in 27 countries, and they feed an aftermarket business (CS&I) that earned $268.0 million, or 31.9% of 2025 revenue. The company holds 169 active U.S. patents and 356 active patents granted in other countries. On the limiting side, the risk factors say the ion implant segment 'includes one company with substantially greater financial, engineering, manufacturing, marketing and customer service and support resources', as well as 'several smaller companies that could provide innovative systems'. U.S. export controls 'exacerbate the risk that Chinese customers will change suppliers to non-U.S. vendors', while Kingstone Semiconductor and CETC 'continue to develop ion implanters for the Chinese domestic market'. 'None of our customers have entered into a long-term agreement requiring it to purchase our products.' Revenue fell to $839.0 million in 2025 from $1,017.9 million in 2024. A full-line position with a large installed base, against a better-resourced rival and new Chinese entrants, is a narrow moat.

Type: intangibles ip

The FY2025 10-K grounds the advantage in owned implant technology rather than contractual lock-in. Its Purion implanters share 'a common platform which enables a unique combination of implant purity, precision, and productivity', and its high energy systems use 'production-proven RF Linac high energy, spot beam technology'. System assembly and testing stays in-house 'due to the high degree of expertise and intellectual property associated with the process and design'. The company holds 169 active U.S. and 356 foreign patents, though it says it is not 'substantially dependent on any single patent or any group of patents'. The installed base supports aftermarket revenue but does not lock customers in: the risk factors say customers often train 'their own staff to maintain and service' equipment and buy parts that are not patent-protected from third parties. Switching costs are therefore the weaker candidate.

Leadership: fast follower

The FY2025 10-K says 'In the market for ion implantation systems, we mainly compete against Applied Materials' and that the two 'are the only ion implant system manufacturers with a full range of implant products'. It claims Axcelis 'has been a market leader in high energy ion implanters for many years' and is 'a technology leader and supplier of choice' in power devices. But its risk factors say the implant segment includes 'one company with substantially greater' resources (unnamed there; Applied Materials is the main rival it names), and it lists 'Achieve market share leadership across all served markets' as a 2026 goal rather than a current fact. No third-party market-share source was fetched, so these are the company's own claims. Which of the two full-line suppliers has the larger overall share is not established by the sources read. Because the only basis for a shared lead is the company's own description, and that description treats share leadership as a goal not yet met, the band is held at fast_follower rather than co_leader.

Pricing power: moderate

The FY2025 10-K reports gross margin of 44.9% in 2025 against 44.7% in 2024. That held steady while revenue fell from $1,017.9 million to $839.0 million, but its risk factors warn that 'if we must lower prices to remain competitive without commensurate cost of goods savings, our gross margin and profitability will be adversely affected'. They also say that if suppliers raise component costs, Axcelis 'may not be able to raise the price of our products to cover all or part of the increased cost'. On the Q2 2026 call (https://www.marketbeat.com/earnings/reports/2026-8-5-axcelis-technologies-inc-stock/), management reported a non-GAAP gross margin of 42.7% (the call states its income-statement measures are non-GAAP unless noted, so it is not directly comparable with the 10-K's GAAP figures), 'slightly below our outlook of 43%', citing CS&I mix and higher than anticipated services costs.

Curated moat judgment grounded in the cited source. source: sec.gov

Compare with…

Value-chain position

Layer: equipment & EDA

• Upstream (suppliers): —
• Downstream (customers): Micron
• Competitors: Applied Materials

A front-end wafer-fab equipment supplier to chipmakers, concentrated in Asia and in power devices. The FY2025 10-K says implanter shipments to Asian customers were 76.0% of 2025 system revenue, international sales 83.7% of total revenue, and the top ten customers 55.2% of net sales. It also says sales to Chinese customers are expected to remain significant under U.S. export-control licensing.

Derived from this company's mapped supply-chain edges and its industry layer.

Signal contribution editorial prior

The moat prior voted +0.06 on the long (~6-month) horizon at weight 0.20 — the swarm call there is bearish (score -0.26, conviction 21).

Editorial prior — subjective, not backtested. It is bounded (±0.6), low-confidence, and never votes on short/medium. See exactly how it voted →

Product lineup

Products & services with an editorial market-share band and technical barrier band — qualitative judgments tied to a cited basis, never invented figures.

What you're looking at

These charts plot Axcelis Technologies's reported income statement, cash flow, and balance sheet from its SEC filings through 2026-08-06. Every figure is as-filed XBRL — none of it is an estimate.

Over the reported window, net income at $120.2M in FY2025.

Our model leans Low-confidence · Neutral on the stock over the medium horizon — a market-direction call, not an earnings forecast. See the Signal tab.

Filings

• 2025Q4 · filed 2026-08-06 source: sec.gov
• 2026Q2 · filed 2026-08-06 source: sec.gov
• 2025Q2 · filed 2026-08-06 source: sec.gov
• 2025Q1 · filed 2026-08-06 source: sec.gov
• 2026Q1 · filed 2026-08-06 source: sec.gov

Key ratios vs peers

Comparing against peers…

Institutional holders (13F, 2026Q2)

TradingPilot-computed columns (% of 13F, % shares out) are derived from as-filed 13F values; only name, shares and value are as-filed.